Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

@article{Li2011PharmacokineticsO,
  title={Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.},
  author={Chun Xiao Li and Christine W. Alvey and Akintunde Bello and Keith D. Wilner and Weiwei Tan},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={e13065}
}
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine kinases. Crizotinib is currently being developed as an orally administered agent in treatment of advanced ALK-positive NSCLC. The recommended clinical dose is 250 mg BID. METHODS Plasma crizotinib concentration data were collected in an ongoing, open-label, multi-center phase I study (J Clin Oncol 28:15s, 2010). A total of 167 patients receiving crizotinib at a dose… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…